Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Status:
Withdrawn
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and activity of the
combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell
lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell
transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Mundipharma K.K. Wyeth is now a wholly owned subsidiary of Pfizer